MDxHealth appoints Michael Holder as Chair of Audit Committee, succeeding Regine Slagmulder, as CFO Ron Kalfus resigns.
Quiver AI Summary
MDxHealth SA announced the appointment of Michael Holder as the new Chair of its Audit Committee, replacing Regine Slagmulder, who completed her term in May. Holder brings over 30 years of experience in various executive roles across biotech and health sectors, including CEO and CFO positions. He has previously led a private investment firm and served as CEO of Sensable Health. The company also shared that CFO Ron Kalfus is resigning to pursue other opportunities, with Scott McMahan stepping in as interim CFO. CEO Michael K. McGarrity expressed enthusiasm for Holder's expertise, which will aid the company's growth in urology markets. Board Chair Koen Hoffman acknowledged the contributions of both Slagmulder and Kalfus to MDxHealth's progress.
Potential Positives
- Michael Holder's appointment as Chair of the Audit Committee brings over 30 years of diverse executive experience, enhancing the company's governance and strategic direction.
- Holder's background in corporate strategy and finance is expected to support MDxHealth's ongoing growth in the urology market.
- The transition in leadership represents a commitment to maintaining strong oversight with the appointment of a well-qualified individual to the Audit Committee following Regine Slagmulder’s term.
Potential Negatives
- The resignation of Ron Kalfus as Chief Financial Officer may indicate potential instability within the executive leadership team, which could affect investor confidence.
- Michael Holder's appointment as Chair of the Audit Committee follows a change in leadership, possibly suggesting a need for enhanced oversight amidst ongoing corporate transitions.
- The press release includes extensive forward-looking statements that may underscore uncertainties regarding the company's future performance and market positioning, leading to potential skepticism from stakeholders.
FAQ
Who has been appointed as the Chair of the Audit Committee at MDxHealth?
Michael Holder has been appointed as the Chair of the Audit Committee at MDxHealth.
What experience does Michael Holder bring to MDxHealth's Board?
Michael Holder brings over 30 years of experience in biotech, medtech, and pharma industries, including CEO and CFO roles.
When will Ron Kalfus depart as CFO at MDxHealth?
Ron Kalfus will depart as CFO on July 30, 2025, after serving until then.
Who will assume the CFO responsibilities after Ron Kalfus?
Scott McMahan, Vice President of Finance and Accounting, will assume the CFO responsibilities on an interim basis.
Where are MDxHealth's headquarters located?
MDxHealth's U.S. headquarters are in Irvine, California, with European headquarters in Herstal, Belgium.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDXH Hedge Fund Activity
We have seen 5 institutional investors add shares of $MDXH stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. removed 936,707 shares (-93.0%) from their portfolio in Q1 2025, for an estimated $1,330,123
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 851,688 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,209,396
- AWM INVESTMENT COMPANY, INC. added 499,992 shares (+10.6%) to their portfolio in Q1 2025, for an estimated $709,988
- MONASHEE INVESTMENT MANAGEMENT LLC removed 208,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $295,360
- PERKINS CAPITAL MANAGEMENT INC added 198,000 shares (+20.1%) to their portfolio in Q1 2025, for an estimated $281,160
- SAMJO MANAGEMENT, LLC removed 192,244 shares (-10.5%) from their portfolio in Q1 2025, for an estimated $272,986
- NORTHERN TRUST CORP added 189,358 shares (+43.4%) to their portfolio in Q1 2025, for an estimated $268,888
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May.
Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $250M private investment company and most recently served as CEO of Sensable Health, an AI-powered wellness program, while also holding board positions at Cytek Biosciences Inc. (NASDAQ: CTKB, where he is Chair of the Audit Committee), and Keyron Medical Ltd. Mr. Holder received an MBA from the Wharton School, a BS in Business from the University of North Carolina, and previously earned his Certified Public Accountant licensure.
Michael K. McGarrity, CEO, commented: “We are incredibly excited to welcome Michael Holder to our Board of Directors as the Chair of our Audit Committee. Michael's remarkable 30-plus years of diverse experience across the biotech, medtech, and pharma industries, combined with his deep expertise in corporate strategy, fundraising, and his financial acumen, will be invaluable as we continue to generate industry-leading growth within the urology markets that we serve.”
In addition, the Company announced that Ron Kalfus has resigned from his position as Chief Financial Officer to pursue other opportunities. Mr. Kalfus will continue to serve in the role of CFO until his departure on July 30, 2025, at which time the CFO responsibilities at mdxhealth will be assumed on an interim basis by Scott McMahan, Vice President of Finance and Accounting.
Mr. McGarrity continued , “On behalf of mdxhealth, I would like to thank Ron for his partnership and contributions during a period of significant growth for our company over the last 6 years. Ron has been a valuable member of our executive leadership team, and we wish him the very best in his future endeavors.”
Koen Hoffman, Board Chair, commented: “On behalf of the Board of Directors, I would like to welcome Michael Holder and thank Regine Slagmulder for her valued service as Chair of our Audit Committee, as well as Ron Kalfus for his service as CFO. Over the years, Regine and Ron have significantly contributed to our progress with the utmost integrity, professionalism and expertise.”
About mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding expected future operating results; and our strategies, positioning, resources, capabilities and expectations for future events or performance. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with global macroeconomic conditions; our ability to successfully and profitably market our products; the acceptance and reimbursement of our products and services by healthcare providers and payers; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the Oncotype DX® GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws..
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.
For more information:
LifeSci Advisors (IR & PR)
John Fraunces
Managing Director
Tel: +1 917 355 2395
[email protected]
[email protected]
Attachment